×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Emphysema Market

ID: MRFR/Pharma/17378-HCR
100 Pages
Garvit Vyas
October 2025

US Emphysema Market Research Report By Type (centrilobular, panlobular), By Diagnosis (imaging test, lung function test, others, chest X-ray, CT scan), By Treatment (medications, therapy, surgery, smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, leukotriene modifiers, pulmonary rehabilitation, nutrition therapy, gene therapy, supplemental oxygen, lung volume reduction surgery, lung transplant, bullectomy) and By End-User (hospitals and clinics, surgical centers, others) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Emphysema Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

US Emphysema Market Summary

As per MRFR analysis, the US emphysema market Size was estimated at 2841.3 USD Million in 2024. The US emphysema market is projected to grow from 2978.53 USD Million in 2025 to 4773.72 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.83% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The US emphysema market is experiencing notable advancements driven by innovative treatment options and a growing focus on preventive care.

  • Advancements in treatment options are enhancing patient outcomes and expanding the therapeutic landscape.
  • The largest segment in the US emphysema market is the pharmaceutical sector, which is witnessing significant innovations.
  • Integration of technology in management is becoming increasingly prevalent, facilitating better patient monitoring and adherence.
  • Rising prevalence of emphysema and increased awareness and education are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 2841.3 (USD Million)
2035 Market Size 4773.72 (USD Million)

Major Players

GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Roche (CH), Teva Pharmaceutical Industries (IL), Mylan (US), Pfizer (US), Merck & Co. (US)

US Emphysema Market Trends

The emphysema market is currently experiencing notable shifts driven by various factors, including advancements in treatment options and an increasing awareness of respiratory diseases. The prevalence of emphysema, a chronic obstructive pulmonary disease, continues to rise, prompting healthcare providers to seek innovative therapies and management strategies. This trend is further supported by a growing aging population, which is more susceptible to respiratory conditions. As a result, pharmaceutical companies are investing in research and development to create more effective medications and therapies tailored to the needs of patients suffering from emphysema. Moreover, the emphasis on preventive care and early diagnosis is reshaping the landscape of the emphysema market. Healthcare systems are increasingly focusing on screening programs and public health initiatives aimed at reducing the incidence of smoking-related diseases. This proactive approach not only enhances patient outcomes but also reduces the overall burden on healthcare resources. The integration of technology in monitoring and managing emphysema is also gaining traction, with telemedicine and digital health solutions becoming more prevalent. These developments indicate a dynamic and evolving market that is likely to continue adapting to the needs of patients and healthcare providers alike.

Advancements in Treatment Options

The emphysema market is witnessing a surge in innovative treatment modalities. New pharmacological agents and therapies are being developed to enhance patient outcomes. This trend is driven by ongoing research aimed at understanding the underlying mechanisms of the disease, leading to more targeted and effective interventions.

Increased Focus on Preventive Care

There is a growing emphasis on preventive measures within the emphysema market. Healthcare providers are prioritizing early diagnosis and intervention strategies to mitigate the progression of the disease. Public health campaigns aimed at smoking cessation and awareness are becoming more prevalent, contributing to a healthier population.

Integration of Technology in Management

The incorporation of technology into the management of emphysema is transforming patient care. Telehealth services and digital monitoring tools are being utilized to enhance patient engagement and adherence to treatment plans. This trend reflects a shift towards more personalized and accessible healthcare solutions.

US Emphysema Market Drivers

Growing Geriatric Population

The growing geriatric population in the US is a significant driver of the emphysema market. As individuals age, the risk of developing chronic respiratory diseases, including emphysema, increases. The US Census Bureau projects that by 2030, nearly 20% of the population will be aged 65 and older. This demographic shift is expected to lead to a higher prevalence of emphysema, necessitating increased healthcare resources and treatment options. The healthcare system will likely need to adapt to accommodate the specific needs of older patients, including tailored therapies and support services, thereby expanding the emphysema market.

Rising Prevalence of Emphysema

The increasing prevalence of emphysema in the US is a critical driver for the emphysema market. According to the CDC, approximately 3.5 million adults in the US have been diagnosed with chronic obstructive pulmonary disease (COPD), which includes emphysema. This rising incidence is attributed to factors such as smoking, environmental pollutants, and occupational hazards. As the population ages, the number of individuals at risk for developing emphysema is expected to grow, thereby expanding the patient base for treatment options. This trend indicates a potential increase in demand for medications, therapies, and healthcare services related to the emphysema market, as healthcare providers seek to manage and treat this chronic condition effectively.

Increased Awareness and Education

Increased awareness and education regarding emphysema and its management are pivotal drivers for the emphysema market. Public health campaigns and educational initiatives have been instrumental in informing both patients and healthcare providers about the risks associated with smoking and environmental factors contributing to emphysema. This heightened awareness has led to earlier diagnosis and intervention, which is crucial for improving patient outcomes. As more individuals recognize the symptoms and seek medical advice, the demand for diagnostic tools and treatment options is likely to rise. Consequently, this trend may result in a more robust market for healthcare services and products related to emphysema management.

Innovations in Pharmaceutical Development

Innovations in pharmaceutical development are significantly influencing the emphysema market. Recent advancements in drug formulations and delivery systems have led to the introduction of novel therapies that target the underlying mechanisms of emphysema. For instance, the development of long-acting bronchodilators and inhaled corticosteroids has improved patient outcomes and adherence to treatment regimens. The market for these medications is projected to reach approximately $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 5%. This growth is driven by the need for more effective management strategies for patients suffering from emphysema, highlighting the importance of ongoing research and development in the pharmaceutical sector.

Regulatory Support for Treatment Accessibility

Regulatory support for treatment accessibility plays a crucial role in shaping the emphysema market. Recent policy changes aimed at improving access to healthcare services and medications for chronic diseases have the potential to enhance treatment options for emphysema patients. Initiatives such as expanded insurance coverage for pulmonary rehabilitation and inhalation therapies are expected to facilitate better management of the disease. Furthermore, the FDA's expedited approval processes for innovative therapies may lead to quicker access to new treatment options for patients. This regulatory environment is likely to foster growth in the emphysema market, as more patients gain access to essential care.

Market Segment Insights

By Type: Centrilobular (Largest) vs. Panlobular (Fastest-Growing)

Centrilobular emphysema represents the largest share within the US emphysema market, characterized by its prominence in smokers and individuals with chronic bronchitis. The condition predominantly affects the upper lobes of the lungs, leading to significant airflow limitation. In contrast, panlobular emphysema, while having a smaller current share, is the fastest-growing segment, particularly among patients with alpha-1 antitrypsin deficiency. This growth is driven by increasing awareness and diagnostic advancements that facilitate earlier detection. The growth trends for these segments are influenced by changing demographics, with an increasing aging population being more susceptible to panlobular emphysema. Moreover, advancements in treatment modalities and the rising prevalence of lung-related diseases contribute to the growth of both segments. With healthcare providers focusing on personalized treatment approaches, the emphasis on identifying and managing types of emphysema is likely to bolster the overall market. Emphasis on patient education and awareness in managing these conditions may also play a crucial role in market expansion.

Centrilobular (Dominant) vs. Panlobular (Emerging)

Centrilobular emphysema is the dominant segment in the market, linked primarily with smoking and known for affecting the upper lobes of the lungs, resulting in significant functional impairment. Its position is strengthened by the high prevalence among smokers and those with chronic pulmonary conditions. On the other hand, panlobular emphysema is emerging as a crucial segment, particularly noted for its association with genetic factors such as alpha-1 antitrypsin deficiency. While it currently holds a smaller share of the market, its growth potential is promising as awareness and detection strategies improve. The rising focus on personalized medicine is fostering interest in panlobular emphysema, aiming to enhance patient outcomes through targeted therapies.

By Diagnosis: Lung Function Test (Largest) vs. Imaging Test (Fastest-Growing)

In the US emphysema market, the Diagnosis segment is predominantly characterized by the Lung Function Test, which holds a significant share, making it the largest among the various testing methodologies. Imaging Tests, while trailing behind in market share, are rapidly gaining traction due to advancements in technology and increasing diagnostic accuracy. Both tests play a vital role in the assessment and management of emphysema patients, ensuring that they receive appropriate and timely care. Growth trends in this segment are influenced by several factors, including the rising prevalence of respiratory diseases and the increasing awareness of early diagnosis. The Lung Function Test remains a standard practice, driven by its effectiveness and cost-efficiency. In contrast, Imaging Tests are emerging as a crucial component, with innovations such as CT scans providing detailed insights into emphysema progression, thus facilitating better treatment decisions and personalized patient care.

Lung Function Test (Dominant) vs. Imaging Test (Emerging)

The Lung Function Test is the dominant methodology within the Diagnosis segment, characterized by its comprehensive assessment of pulmonary function. Its extensive usage is supported by clinical guidelines and its ability to deliver immediate results, making it a cornerstone of emphysema diagnosis. On the other hand, Imaging Tests represent an emerging trend, particularly with the introduction of sophisticated technologies like high-resolution CT scans that offer a clearer view of lung pathology. As these methodologies evolve, Imaging Tests are increasingly becoming indispensable for specialists, enhancing the diagnostic process and contributing significantly to the understanding of emphysema's impact on lung structure. They are poised for rapid growth as they complement conventional tests and improve diagnostic confirmations.

By Treatment: Medications (Largest) vs. Therapy (Fastest-Growing)

The treatment segment within the US emphysema market is dominated by medications, which hold the largest share due to their established efficacy in managing symptoms and improving patient outcomes. Medications often include bronchodilators and corticosteroids, which are crucial for enhancing airflow and reducing inflammation. In contrast, therapy constitutes a rapidly growing sector, primarily driven by increasing awareness and acceptance of non-pharmacological interventions, leading to a more balanced approach in treating emphysema. Growth trends indicate a shift towards personalized treatment plans that combine medications and therapy for better patient management. The rising prevalence of emphysema, influenced by factors such as smoking and environmental pollutants, further propels demand for innovative therapies. Enhanced patient education and supportive care models also contribute significantly to the expansion of the therapy segment, as patients seek more comprehensive treatment options concurrently with traditional medications.

Medications: Bronchodilators (Dominant) vs. Therapy: Pulmonary Rehabilitation (Emerging)

Bronchodilators are the dominant force in the US emphysema market, known for their immediate relief in obstructive symptoms. These medications help relax and open airways, enabling better airflow, thus significantly improving the quality of life for patients. On the other hand, pulmonary rehabilitation emerges as a vital component of comprehensive emphysema management. This therapeutic approach combines physical exercises, education, and psychological support, addressing the multifaceted needs of emphysema patients. As healthcare providers increasingly recognize the importance of holistic treatment strategies, there is a growing focus on integrating therapeutic interventions alongside medications to optimize patient outcomes in the challenging landscape of emphysema management.

By End-User: Hospitals (Largest) vs. Surgical Centers (Fastest-Growing)

In the US emphysema market, hospitals serve as the largest end-user segment, commanding a significant share due to their comprehensive healthcare services and respiratory care capabilities. Clinics also contribute to the market, but their share is relatively smaller compared to hospitals. Surgical centers have begun to emerge as important players, capturing an increasing portion of the market as they adopt advanced technologies and specialize in outpatient procedures. The growth trends in the end-user segment reveal that surgical centers are the fastest-growing category. This growth is driven by the rising demand for minimally invasive procedures and a focus on cost-effective treatment options. Hospitals continue to dominate, but surgical centers are gaining traction by improving patient flow and outcomes with specialized care. This juxtaposition highlights the evolving landscape of care for patients with emphysema in the market.

Hospitals (Dominant) vs. Surgical Centers (Emerging)

Hospitals represent the dominant force in the US emphysema market, providing extensive facilities and specialized departments for managing respiratory diseases. Their ability to deliver comprehensive care, including emergency services, makes them pivotal in treating patients with emphysema. Conversely, surgical centers are emerging as valuable alternatives, focusing on elective and outpatient procedures that cater to a growing patient base seeking less invasive treatments. They appeal to both patients and insurers due to their efficiency and reduced costs, thus positioning themselves as key components in the broader healthcare ecosystem. The collaboration between hospitals and surgical centers is likely to define future care models, enhancing patient outcomes and satisfaction.

Get more detailed insights about US Emphysema Market
Request Free Sample

Key Players and Competitive Insights

The emphysema market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as GlaxoSmithKline (GB), Boehringer Ingelheim (DE), and AstraZeneca (GB) are actively shaping the market dynamics through their distinct operational strategies. GlaxoSmithKline (GB) emphasizes research and development, particularly in novel therapies aimed at improving patient outcomes. Boehringer Ingelheim (DE) focuses on expanding its portfolio through strategic acquisitions and collaborations, while AstraZeneca (GB) is leveraging its strong pipeline of biologics to enhance its market presence. Collectively, these strategies foster a competitive environment that prioritizes innovation and responsiveness to patient needs.

In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they drive advancements in treatment options and patient care. This competitive structure allows for a dynamic interplay between established firms and emerging players, fostering an environment ripe for innovation.

In October 2025, Boehringer Ingelheim (DE) announced a strategic partnership with a leading telehealth provider to enhance patient access to care. This collaboration aims to integrate digital health solutions into the management of emphysema, potentially improving patient adherence to treatment regimens. The strategic importance of this move lies in its alignment with the growing trend towards digital health, which is likely to enhance patient engagement and outcomes.

In September 2025, AstraZeneca (GB) launched a new inhalation therapy specifically designed for emphysema patients, which has shown promising results in clinical trials. This product introduction not only strengthens AstraZeneca's portfolio but also reflects its commitment to addressing unmet medical needs in the emphysema space. The launch is expected to capture significant market share, particularly among patients seeking innovative treatment options.

In August 2025, GlaxoSmithKline (GB) expanded its research initiatives by investing in artificial intelligence (AI) to streamline drug discovery processes. This investment underscores the company's commitment to leveraging technology for faster and more efficient development of new therapies. The integration of AI into research could potentially accelerate the introduction of novel treatments, thereby enhancing GlaxoSmithKline's competitive edge in the market.

As of November 2025, the competitive trends in the emphysema market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies position themselves in the market, emphasizing the importance of delivering superior patient outcomes through innovative solutions.

Key Companies in the US Emphysema Market market include

Industry Developments

The US Emphysema Market has witnessed significant developments in recent months, particularly driven by advancements in treatment options. Vertex Pharmaceuticals has made strides in Research and Development for innovative therapies aimed at treating emphysema. AstraZeneca continues to expand its pipeline with new inhaled therapies, focusing on improving patient outcomes. Novartis and GlaxoSmithKline are engaged in ongoing studies targeting the inflammation pathways associated with emphysema. 

Additionally, Eli Lilly and Bristol Myers Squibb are collaborating on a clinical study to evaluate the efficacy of a combination therapy that could enhance breathing function in patients. There have been reports of market growth, with companies like Gilead Sciences and United Therapeutics experiencing a valuation increase due to their novel approaches to respiratory diseases. In terms of mergers and acquisitions, in July 2023, Boehringer Ingelheim acquired a small biotech firm specializing in lung diseases, enhancing their portfolio in the emphysema space. Pfizer and Amgen have also announced partnerships aimed at accelerating the development of therapies that target emphysema-related complications.

Market dynamics show an increasing investment in treatments, reflecting an ongoing commitment to addressing this chronic condition.

Future Outlook

US Emphysema Market Future Outlook

The emphysema market is projected to grow at a 4.83% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing patient awareness.

New opportunities lie in:

  • Development of telehealth platforms for remote patient monitoring
  • Investment in personalized medicine for tailored treatment plans
  • Expansion of home-based oxygen therapy solutions to enhance patient convenience

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

Market Segmentation

US Emphysema Market Type Outlook

  • centrilobular
  • panlobular

US Emphysema Market End-User Outlook

  • hospitals and clinics
  • surgical centers
  • others

US Emphysema Market Diagnosis Outlook

  • imaging test
  • lung function test
  • others

US Emphysema Market Treatment Outlook

  • medications
  • therapy
  • surgery

Report Scope

MARKET SIZE 2024 2841.3(USD Million)
MARKET SIZE 2025 2978.53(USD Million)
MARKET SIZE 2035 4773.72(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 4.83% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Roche (CH), Teva Pharmaceutical Industries (IL), Mylan (US), Pfizer (US), Merck & Co. (US)
Segments Covered Type, Diagnosis, Treatment, End-User
Key Market Opportunities Advancements in targeted therapies and personalized medicine enhance treatment options in the emphysema market.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the emphysema market.
Countries Covered US

Leave a Comment

FAQs

What is the expected size of the US Emphysema Market in 2024?

The US Emphysema Market is expected to be valued at 2.5 billion USD in 2024.

What is the projected market size for the US Emphysema Market by 2035?

By 2035, the US Emphysema Market is projected to reach a value of 4.5 billion USD.

What is the expected compound annual growth rate (CAGR) for the US Emphysema Market from 2025 to 2035?

The market is anticipated to grow at a CAGR of 5.489% from 2025 to 2035.

Which segments of the US Emphysema Market are expected to dominate by 2035?

By 2035, the centrilobular segment is expected to be valued at 2.2 billion USD, while the panlobular segment will reach 2.3 billion USD.

Who are the major players in the US Emphysema Market?

Key players in the market include Vertex Pharmaceuticals, AstraZeneca, Novartis, GlaxoSmithKline, and Eli Lilly.

What growth opportunities exist within the US Emphysema Market?

Emerging trends and innovations in treatment options present significant growth opportunities in the US Emphysema Market.

What challenges are currently faced by the US Emphysema Market?

The market faces challenges such as regulatory hurdles and competitive pressures from new entrants and therapies.

How does the US Emphysema Market size compare between the centrilobular and panlobular types in 2024?

In 2024, the centrilobular type is valued at 1.2 billion USD, while the panlobular type is slightly higher at 1.3 billion USD.

What impact do economic conditions have on the US Emphysema Market?

Current economic conditions may influence product availability and pricing strategies within the US Emphysema Market.

What is the projected market growth rate for the US Emphysema Market in different segments?

The market is expected to see significant growth across both centrilobular and panlobular segments over the forecast period.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓